ClinicalTrials.gg
CompletedNCT01536938Updated Mar 7, 2025Results posted

LEO 90100 in the Treatment of Psoriasis Vulgaris

A Phase 2 interventional study of LEO 90100 and Calcipotriol in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
20th of 47
303 · median 200
Started
2012
with 3 others
Phase 2
9 of 47
none open now
Registered
19th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 20th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 19th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained prior to any trial related activities (including ).
  • Age 18 years or above
  • Either sex
  • Any race or ethnicity
  • All skin types
  • Females of must have a negative pregnancy test at Day 0 (Visit 1).
  • Females of childbearing potential must agree to use a highly effective method of during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).
  • Able to communicate with the investigator and understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:

    • etanercept - within 4 weeks prior to randomisation
    • adalimumab, alefacept, infliximab - within 8 weeks prior to randomisation
    • ustekinumab - within 16 weeks prior to randomisation
    • other products - 4 weeks/5 half-lives (whichever is longer)
  • Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., , retinoids, methotrexate, ciclosporin and other ) within 4 weeks prior to randomisation.
  • Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.
  • PUVA therapy within 4 weeks prior to randomisation.
  • UVB therapy within 2 weeks prior to randomisation.
  • Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial sunlight (including tanning booths, sun lamps, etc.) during the study.
  • Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the study.
  • Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
  • Subjects with any of the following conditions present on the treatment area: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, icthyosis, ulcers and wounds.
  • Other inflammatory skin disorders (e.g. seborrhoeic dermatitis or contact dermatitis) on the treatment area that may confound the evaluation of psoriasis vulgaris.
  • Known or suspected disorders of calcium metabolism associated with hypercalcaemia.
  • Known or suspected severe renal insufficiency or severe hepatic disorders.
  • Known or suspected to component(s) of the products.
  • Current participation in any other interventional clinical study.
  • Previously randomised in this study.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
303 participants (actual)

Study arms

  • Active comparator
    Calcipotriol

    Calcipotriol aerosol foam: calcipotriol 50 mcg/g. Applied once daily for up to 4 weeks

    Drug: Calcipotriol

  • Active comparator
    Betamethasone

    Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate) Applied once daily for up to 4 weeks

    Drug: Betamethasone

  • Experimental
    LEO 90100

    LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) Applied once daily for up to 4 weeks

    Drug: LEO 90100

Interventions

06

What researchers measure

Primary outcomes

  1. Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.

    Assessment of disease severity (Plaque thickening, Scaling and Erythema) using a 5-point scale (Clear, Almost clear, Mild, Moderate, Severe), based on the condition of the disease at the time of evaluation.

    Time frame: 4 weeks

07

Results

Posted Dec 9, 2015

Participant flow

First Subject First Visit: 07-MAY-2012 Last Subject Last Visit: 10-OCT-2012

Participant flow — Overall Study
MilestoneLEO 90100Betamethasone DipropionateCalcipotriol Aerosol Foam
Started100101101
Completed949493
Not completed678

Outcome measures

PrimarySubjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.

Assessment of disease severity (Plaque thickening, Scaling and Erythema) using a 5-point scale (Clear, Almost clear, Mild, Moderate, Severe), based on the condition of the disease at the time of evaluation.

Time frame:
4 weeks
Reported as:
Number · participants
Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.
participantsLEO 90100Betamethasone DipropionateCalcipotriol Aerosol Foam
Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.453115

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LEO 90100—1/100 (1%)0/100 (0%)
Betamethasone Dipropionate—0/99 (0%)0/99 (0%)
Calcipotriol Aerosol Foam—0/99 (0%)0/99 (0%)
Most frequent serious events
Most frequent serious events
EventLEO 90100Betamethasone DipropionateCalcipotriol Aerosol Foam
HypersensitivityImmune system disorders1/1000/990/99

Baseline characteristics

Age, Continuous
Age, Continuous(years)LEO 90100Betamethasone DipropionateCalcipotriol Aerosol FoamTotal
Mean47.4 ± 14.849.0 ± 14.450.7 ± 14.749.0 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)LEO 90100Betamethasone DipropionateCalcipotriol Aerosol FoamTotal
Female474540132
Male535661170
08

Study locations

33 sites
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • Skin Surgery Medical Group, Inc
    San Diego, California 92117, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Colorado Medical Research Center, Inc
    Denver, Colorado 80210, United States
  • Horizons Clinical Research Center
    Denver, Colorado 80220, United States
  • Dermatology Associates and Research
    Coral Gables, Florida 33134, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Altman Dermatology Associates
    Arlington Heights, Illinois 60005, United States
  • Glazer Dermatology
    Buffalo Grove, Illinois 60089, United States
  • Clinical Research Advantage, Inc./Hudson Dermatology, LLC
    Evansville, Indiana 47714, United States
  • Dawes Fretzin Clinical Research Group
    Indianapolis, Indiana 46256, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Owensboro Dermatology Associates
    Owensboro, Kentucky 42303, United States
  • David Fivenson, MD, PLC
    Ann Arbor, Michigan 48103, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Derm Center
    Troy, Michigan 48084, United States
  • Grekin Skin Institute
    Warren, Michigan 48008, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Psoriasis Treatment Center of Central NJ
    East Windsor, New Jersey 08520, United States
  • The Dermatology Group, PC
    Verona, New Jersey 07044, United States
  • Derm Research Center of New York
    Stony Brook, New York 11790, United States
  • Philadelphia Institute of Dermatology
    Fort Washington, Pennsylvania 19034, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Clinical Trials of Texas, Inc
    San Antonio, Texas 78229, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Progressive Clinical Research
    San Antonio, Texas 78229, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Olesen M, Lowson D, Yamauchi P. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol. 2016 Feb;9(2):34-41. Epub 2016 Feb 1. PubMed 27313822 ↗
  • Veverka KA, Hansen JB, Yaloumis M, Kircik L, Stein Gold L. Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials. J Drugs Dermatol. 2021 Aug 1;20(8):822-828. doi: 10.36849/JDD.5743. PubMed 34397196 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Sep 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 3 years 3 months after primary completion. A results delay was requested in Oct 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2012
First posted
Feb 22, 2012
Start
May 2012
Primary completionActual
Sep 2012
CompletionActual
Nov 2012
Results delay requested
Oct 22, 2013
Results first posted
Dec 9, 2015
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01536938
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Feb 22, 2012
Start date
May 2012
Primary completion
Sep 2012
Completion
Nov 2012
Results posted
Dec 9, 2015
Last update
Mar 7, 2025

Study contacts

Mark Lebwohl, M.D.
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion